Preživljavanje graftova i bolesnika sa transplantiranim bubregom u periodu od 1996. do 2017. godine na Vojnomedicinskoj akademiji, Beograd, Srbija

  • Neven Vavić Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Aleksandra Tomić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Predrag Aleksić Military Medical Academy, Clinic for Urology, Belgrade, Serbia
  • Katarina Obrenčević Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Milorad Radojević Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Ljiljana Ignjatović Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Predrag Marić Military Medical Academy, Clinic for Urology, Belgrade, Serbia
  • Mirko Jovanović Military Medical Academy, Clinic for Urology, Belgrade, Serbia
  • Nemanja Rančić Military Medical Academy, Clinic for Vascular Surgery, Belgrade, Serbia
  • Djoko Maksić Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP190313091V
Ključne reči: životno doba, faktor;, kreatinin;, alograft;, graft, preživljavanje;, transplantacija bubrega;, pol, faktor.

Sažetak


Uvod/Cilj. Transplantacija bubrega je najbolji i poželjan način lečenja bolesnika sa završnim stadijumom bubrežne bolesti, s obzirom na to da omogućava bolje preživljavanje i kvalitet života u poređenju sa dijalizom. Cilj rada bio je da se prikažu rezultati jednog centra (Vojnomedicinska akademija u Beogradu, Srbija) u preživljavanju bolesnika i alografta posle transplantacije bubrega tokom perioda od 1996. do 2017. godine. Metode. Sprovedena je retrospektivna kohortna studija. Parametri od interesa bili su preživljavanje alografta i bolesnika sa transplantiranim bubregom, a analizirani su i starost, pol, nivoi kreatinina u serumu i indukciona terapija posle transplantacije. Rezultati. Od ukupno 386 bolesnika sa transplantiranim bubregom, kod 316 bolesnika je urađena transplantacija od živog donora, dok je kod 70 bolesnika urađena transplantacija bubrega od kadaveričnog donora. Predijalizna transplantacija bubrega je urađena kod 29 (7,5%) bolesnika, dok je transplantacija bubrega od donora sa nepodudarnom krvnom grupom urađena kod 21 (5,4%) bolesnika. Jednogodišnje, petogodišnje, desetogodišnje i dvadesetogodišnje preživljavanje bolesnika posle transplantacije bubrega u ispitivanoj grupi bilo je 97,7%, 95,3%, 93,8% i 91,7%, redom, dok je preživljavanje grafta u istim periodima iznosilo 93,8%, 85,5%, 78,5% i 73,3%, redom. Zaključak. Rezultati preživljavanja grafta i bolesnika u programu transplantacije bubrega na Vojnomedicinskoj akademiji su dobri i u skladu su sa onima u vodećim svetskim medicinskim centrima.

Reference

Dávila FA, Luna RD, Rey DAP. Analysis of post-transplant renal graft survival. Rev Colomb Nefrol 2015; 2(2): 95‒100.

Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labboz-zetta M, Poma P, et al. Pharmacogenetic considerations for op-timizing tacrolimus dosing in liver and kidney transplant pa-tients. World J Gastroenterol 2013; 19(48):9156-73.

Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341(23): 1725‒30.

Wang JH, Skeans MA, Israni AK. Current Status of Kidney Transplant Outcomes: Dying to Survive. Adv Chronic Kidney Dis 2016; 23(5): 281‒6.

Foroncewicz B, Mucha K, Ciszek M, Małkowski P, Durlik M, Szmidt J, et al. A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. Ann Transplant 2013; 18: 384‒92.

Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357(25): 2562‒75.

Coemans M, Süsal C, Döhler B, Anglicheau D, Giral M, Bestard O, et al. Analyses of the short- and long-term graft survival af-ter kidney transplantation in Europe between 1986 and 2015. Kidney Int 2018; 94(5): 964‒73.

Neylan JF. Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multi-center, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30(4): 1355‒8.

Balint B, Pavlovic M, Jevtic M, Hrvacevic R, Ignjatovic L, Ostojic G, et al. Simple "closed-circuit" group-specific immunoadsorp-tion system for ABO-incompatible kidney transplants. Trans-fus Apher Sci 2007; 36(3): 225‒33.

Ignjatović L, Kovacević Z, Jovanović D, Vavić N, Paunić Z, Radojević M, et al. Our first experiences in applying an original method for removal of ABO-isoagglutinins in ABO-incompatible kid-ney recipients. Vojnosanit Pregl 2009; 66(2): 117‒22.

Balint B, Pavlovic M, Todorovic M, Jevtic M, Ristanovic E, Ignjatovic L. The use of original ex vivo immunoadsorption and "multi-manner" apheresis in ABO/H-mismatched kidney transplants--A phase II clinical study. Transfus Apher Sci 2010; 43(2): 141‒8.

Gondos A, Döhler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 2013; 95(2): 267‒74.

Gruessner R, Jie T, Porubsky M, Rana A, Gruessner A. Compari-son of 20-Year Patient and Graft Survival for All Types of Solid Organ Transplants (Txs) [abstract]. Am J Transplant 2013; 13 (Suppl 5). Available from: https://atcmeetingabstracts.com/abstract/comparison-of-20-year-patient-and-graft-survival-for-all-types-of-solid-organ-transplants-txs/

Modi RM, Tumin D, Kruger AJ, Beal EW, Hayes D Jr, Hanje J, et al. Effect of transplant center volume on post-transplant survival in patients listed for simultaneous liver and kidney transplantation. World J Hepatol 2018; 10(1): 134‒41.

Penninga L, Wettergren A, Chan AW, Steinbrüchel DA, Gluud C. Calcineurin inhibitor minimisation versus continuation of cal-cineurin inhibitor treatment for liver transplant recipients. Cochrane Database Syst Rev 2012; 3: CD008852.

Vavić N, Rančić N, Cikota-Aleksić B, Magić Z, Cimeša J, Obrenčević K, et al. The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation. Vojnosanit Pregl 2016; 73(7): 663‒7.

Stratta P, Quaglia M, Cena T, Antoniotti R, Fenoglio R, Menegotto A, et al. The interactions of age, sex, body mass index, genet-ics, and steroid weight-based doses on tacrolimus dosing re-quirement after adult kidney transplantation. Eur J Clin Pharmacol 2012; 68(5): 671‒80.

Stefanović N, Cvetković T, Veličković-Radovanović R, Jevtović-Stoimenov T, Stojanović D, Živković N. Significance of CYP3A5 gene polymorphism in Serbian renal transplant patients. Acta Medica Medianae. 2013; 52(1): 33‒7.

Vavic N, Rancic N, Dragojevic-Simic V, Draskovic-Pavlovic B, Bokonjic D, Ignjatovic L, et al. The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. Eur J Drug Metab Pharmacokinet 2014; 39(4): 243‒53.

Orantes CM, Herrera R, Almaguer M, Brizuela EG, Núñez L, Alvarado NP, et al. Epidemiology of chronic kidney disease in adults of Salvadoran agricultural communities. MEDICC Rev 2014; 16(2): 23‒30.

Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and re-sults for organ donation and transplantation in the United States, 2004. Am J Transplant 2005; 5(4 Pt 2): 843‒9.

Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13(5): 1358‒64.

Maksic DJ, Hrvacevic R, Maric M, Aleksic S, Elakovic D, Ignjatovic L, et al. Peritoneal dialysis and kidney transplantation. Vojno-sanit Pregl 2001; 58(4): 353‒56. (Serbian)

Delmonico FL. Analyzing risk factors of renal transplant out-come. Transplantation 2000; 69(1): 1‒2.

Serbian Society of Nephrology. Annual report on dialysis and kid-ney transplantation in Serbia, 2011. Belgrade: Serbian Society of Nephrology; 2013.

El-Agroudy AE, Wafa EW, Sabry AA, Neamatalla AH, Khalel AA, Isamil AM, et al. The health of elderly living kidney do-nors after donation. Ann Transplant 2009; 14(2): 13‒9.

Collins BH, Kulkarni S, Johnston TD, David Kim E, Talavera F. Renal transplantation. Available from: http://emedicine.medscape.com/article/430128-overview#showall

Thukral S, Kumar D, Ray DS. Comparative analysis of ABO-incompatible kidney transplantation with ABO-compatible transplantation: A single-center experience from Eastern In-dia. Saudi J Kidney Dis Transpl 2019; 30(1): 97–107.

Okumi M, Kakuta Y, Unagami K, Takagi T, Iizuka J, Inui M, et al. Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience. Transl Androl Urol 2019; 8(2): 126–33.

Takahashi K, Saito K. ABO-incompatible kidney transplanta-tion. Transplant Rev (Orlando) 2013; 27(1): 1‒8.

Abramowicz D, Hazzan M, Maggiore U, Peruzzi L, Cochat P, Oberbauer R, et al. Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a liv-ing donor improve outcomes after transplantation? A system-atic literature review and position statement by the Descartes Working Group and ERBP. Nephrol Dial Transplant 2016; 31(5): 691‒7.

Milton CA, Russ GR, McDonald SP. Pre-emptive renal trans-plantation from living donors in Australia: effect on allograft and patient survival. Nephrology (Carlton) 2008; 13(6): 535‒40.

Objavljeno
2022/05/11
Broj časopisa
Vol. 79 Br. 3 (2022)
Rubrika
Originalni članak